420 Magazine Background

syndros

  1. Ron Strider

    Why This Marijuana Stock Crashed 18.5% In August

    A lawsuit tied to the marketing of its fentanyl opioid spray caused Insys Therapeutics' shares to tumble last month. What happened Arizona's attorney general is suing Insys Therapeutics over its marketing of the fentanyl opioid spray, Subsys, and that news caused the company's shares to...
  2. Ron Strider

    This Struggling Marijuana Stock Finally Launched Its Highly Anticipated Drug

    If you look around, chances are you won't find many marijuana stocks struggling. In fact, over the trailing one-year period, 12 out of 13 pot stocks with a market cap above $200 million had risen, with a majority up by at least 100%! Marijuana stocks are mostly budding A pretty steady...
  3. Ron Strider

    The Only Marijuana Stock To Rocket Higher By Double-Digit Percentage Last Week

    Chances are that if investors took a good look around, they'd struggle to find an industry growing as fast as the legal weed industry, which is what makes marijuana stocks such an attractive lure. According to the "Marijuana Business Factbook 2017," a recently released report from Marijuana...
  4. K

    INSYS Therapeutics Jumps On FDA Approval Of Cannabis-Based Drug

    Shares of INSYS Therapeutics Inc are trading 15 percent higher this morning, after the company announced that its cannabis-based medication has been approved by the United States Food and Drug Administration (FDA). The innovative drug, which is called Syndros, is an orally taken liquid form of a...
  5. K

    INSYS Therapeutics Jumps On FDA Approval Of Cannabis-Based Drug

    Shares of INSYS Therapeutics Inc are trading 15 percent higher this morning, after the company announced that its cannabis-based medication has been approved by the United States Food and Drug Administration (FDA). The innovative drug, which is called Syndros, is an orally taken liquid form of a...
  6. K

    Insys Therapeutics Is Hoping Syndros Is Its Blockbuster Marijuana Ticket

    Summary Insys has a PDUFA for Syndros scheduled for July 1. The drug is a sublingual spray reformulation of its currently marketed Marinol. An approval is a potential double-digit upside catalyst for the company. There are risks, and the company has a chequered past, the fallout...